Lupin Limited (LUPIN)
Investor Presentation
Investor Presentation - Q1 FY27
- Sales 82.2bn INR +33% y-y; EBITDA 24.6bn INR (margin 30.0%, +340 bps y-y); PAT 14.2bn INR +16% y-y
- India business grew 14% with 7 new product launches; plans 20+ launches in FY27
- US sales up 30% y-y; 3 new product launches in Q1; plans 15+ launches in FY27
- Strong regulatory compliance with multiple FDA approvals and remediation ongoing
- R&D spend steady at 7.4% of sales; Capex increased to 3.4bn INR
- Sustainability leadership with top pharma ESG rating and multiple awards
- Focus on complex generics, biosimilars, and specialty products pipeline
- Continued cost optimization and digital initiatives to support growth
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 LUPIN — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add LUPIN to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Lupin Limited
Important.
The summary above is generated automatically from Lupin Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.